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A B S T R A C T
In recent years, platelet proteomics has been applied successfully to the study of cardiovascular
diseases (CVDs). It is very well known that platelets play a pivotal role in the pathophysiological
mechanisms underlying many CVDs, especially acute coronary syndromes (ACSs), since they are
implied in thrombus formation after atheroma plaque rupture. This is the reason why molecules
involved in platelet activation and aggregation are primary targets for treatment of ACSs. Many
efforts are aimed at ﬁnding drugs that inhibit platelet activation; however it is difﬁcult to separate
the therapeutic beneﬁts from harmful effects because pathological and physiological functions of
platelets are due to the same mechanisms. Given that platelets lack a nucleus, proteomics is regarded
as an ideal method to approach their biochemistry. Current platelet proteomic studies are focusing on
the identiﬁcation of platelet molecular and functional changes in normal and pathological states,
enriching the comprehension of platelet biological function, and screening for new biomarkers
and antiplatelet agents. In the present article, we introduce the reader to platelet biology and
function, and revise recent advances in platelet proteomics applied to the study of CVDs, including a
special emphasis on sample preparation requirements for proteome analysis of platelet clinical
samples.
ã 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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1.1. Platelet deﬁnition, biogenesis and subpopulations
Platelets are specialized annucleate mammalian blood cells
averaging 2–3 mm in diameter and 0.5 mm in thickness. They have
discoid shape under normal physiological conditions, and their
half-life is 10 days in peripheral blood. Platelets derive from
megakaryocytes (MKs), which are unique polyploid hematopoietic
cells that are found only in mammals and are specialized to
produce and release platelets into the blood circulation. Although
MKs arise in the bone marrow, they can migrate and nest at non-
marrow sites, reason why platelet biogenesis (thrombopoiesis) has
been proposed to take place not only in the bone marrow but also
in lungs and blood. Different stages of platelet development have
been observed in all these three locations.
For a long time it has been questioned whether the MKs present
in the bone marrow, in the lungs or in the blood, are responsible for
the greater production of platelets. For example, the lungs are
reservoirs for megakaryocytes and platelets, releasing them in
response to certain stimuli. Platelets continuously circulate through
pulmonary vessels, contributing to lung defense, disease, and
remodeling, being the effectors of injury in a variety of pulmonary
disorders and syndromes [1]. The estimated contribution of
pulmonary MKs to total platelet production remains unclear, but
in theory platelets and MKs may reach the pulmonary circulation
completing their development into platelets in lung capillaries.
Among the two critical functions of platelets, which are
adhesion at site of vascular injury and promotion of thrombin
generation, it is assumed that all platelets are equally able to satisfy
the former one. Nevertheless, in the last decade some studies
suggest that some platelets have a greater ability to promote
thrombin generation. Within a thrombus, there are clearly
distinguishable platelets with different surface properties. Differ-
ent platelet populations and their functions were recently
reviewed by Heemskerk et al. [2], and are brieﬂy described below.
Close to collagen ﬁbers, there is a population of highly activated
platelets arranged as patches around the thrombus. These platelets,
known as procoagulant platelets, have a rounded structure, expose
PS in their surface, have a sustained calcium-induced morphology,
the ability to bind coagulation factors, and produce procoagulant
microvesicles (MVs).
Coated-platelets are another subpopulation formed after
platelet stimulation with collagen plus thrombin, although some
studies demonstrated that an indistinguishable subpopulation of
cells can be produced by stimulation with other agonists pairs or
even with single agonists [3–6]. Coated-platelets show high levels
of several a-granule procoagulant-proteins on their surface (i.e.
FV, ﬁbrinogen, thrombospondin, vWF), expose high levels of
surface PS, are functional in their ability to bind FXa and generate
an active prothrombinase complex, bind serotonin-conjugated
proteins, and also shed MVs. The physiological signiﬁcance ofcoated-platelets is still unknown, although it is speculated that
they could be signiﬁcant contributors to thrombotic process. The
potential clinical relevance of coated-platelets in hemostasis may
be the contribution to a hemorrhagic or thrombotic phenotype.
Thus, a low level of coated-platelets is correlated with the
appearance of spontaneous intracerebral hemorrhages [7] and
with bleeding diathesis [8], while a high amount of them seems to
correlate with transient ischemic attack and ischemic stroke [9,10],
and with patients with a history of arterial or venous thrombosis
[11]. Coated-platelets also appear to have an impact on the
bleeding phenotype in severe hemophilia [12] among other
diseases.
In a thrombus, there are also aggregate-forming platelets. These
platelets are characterized by the presence of active aIIbb3 in their
surfaces and ﬁbrinogen binding to this receptor. Under coagulant
conditions, procoagulant platelets produce FXa and thrombin
outside the platelet plug, whereas aggregating and clot-retracting
platelets are responsible for plug consolidation and clot retraction.
A ﬁnal category of platelets are apoptotic and necrotic platelets,
characterized by an apoptotic PS exposure, which appears to rely
on caspase activation. Although several in vitro studies have
reported that these platelets have a coagulant potential and
support thrombin generation, their role in physiological conditions
is questionable, as they are rapidly taken up by scavenging cells
present in the blood circulation. Moreover, it has been suggested
that apoptotic and necrotic platelets are activated by a necrotic cell
death pathway [13].
1.2. Platelet function
Platelets main function in hemostasis was recognized more
than a century ago [14]; indeed, low platelet count is responsible
for hemorrhage and prolonged bleeding time, even despite normal
coagulation [15]. Nowadays some other non-hemostatic crucial
biological functions are known in relation to platelets, such as
inﬂammation [16], immunity [17,18], malignancy [19] and
maintenance of vascular integrity [20].
1.2.1. Role of platelets in hemostasis, thrombosis and cardiovascular
disease
Under normal conditions, endothelial cells of the vessel walls
synthesize prostaglandin I2 (PGI2) and nitric oxide (NO) as
inhibitors of platelet function, acting synergistically [21–23]. They
have also ecto-ADPase (CD39) activity, which metabolizes ADP
(platelet activator) to adenosine (platelet inhibitor) [24,25]. These
three mechanisms working coordinately inhibit platelet activation.
When the endothelium is damaged, these mechanisms are altered
and subendothelial matrix is exposed undergoing potent platelet-
activation and shape change, leading to platelet plug formation in
order to avoid excessive bleeding. Thrombus generation starts with
a platelet plug formation followed by stabilization of this plug
through ﬁbrin deposition (coagulation). Primary platelet adhesion
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proteins exposition, which engages speciﬁc receptors on the
platelet surface. Firm adhesion of platelets is associated with
granule secretion and extensive cytoskeletal remodeling, resulting
in the exposure of a highly reactive surface promoting the
recruitment of additional platelets. This process is principally
inﬂuenced by the mobilization of intracellular calcium, considered
the principal initiator of ﬁbrinogen-receptor activation (integrin
aIIbb3) and granule secretion. The content of these granules, along
with thrombin generated on the platelet surface, act as a positive
feedback signals to attract more platelets to the site of injury and to
activate them. Factors secreted from platelets include high
concentrations of secondary agonists such as ADP, adrenaline,
serotonin and thromboxane A2 (TXA2), each of which binds to
speciﬁc receptors of circulating platelets contributing to this
positive-feedback.
Under pathological conditions exaggerated platelet activation
can occur, leading to a pathological thrombosis, which can develop
in coronary artery disease (CAD), stroke and peripheral vascular
occlusions [26]. The development of a platelet-rich thrombus at
the site of atherosclerotic plaque can lead to occlusion of blood
vessels, underlying cause of acute cardiovascular events.
Cardiovascular diseases (CVDs) are the leading cause of death
all over the world [27] and this is the reason why cardiovascular
research has huge relevance. In the last decades many basic and
clinical studies have been done due to the urgent need to shed light
into the complex mechanisms that underlay these diseases and
their progress. CVDs include a number of conditions which affect
structure or function of the cardiovascular system. They comprise
CADs, vascular diseases, arrhythmias, heart failure, heart valve
disease, congenital heart disease, cardiomyopathy, pericardial
disease and aorta disease. In the last few years much progress has
been made in the study of CVDs, but there is still a great need to
understand deeply the physiopathology of this set of diseases.
Coronary artery disease is the most common type of heart
disease and cause of heart attacks. The primary cause of CAD is the
disruption of the atherosclerotic plaque in a coronary artery
followed by the formation of a thrombus in the site of injury
blocking totally or partially the blood ﬂow to the heart. Patients
suffering from CAD can be divided into two groups; those suffering
from stable angina (SA) which is a predictable pattern of chest pain
due to narrow of a coronary artery, and acute coronary syndromes
(ACS) which refers to a set of clinical symptoms related to acute
myocardial ischemia.
Acute coronary syndromes are subdivided into ST-elevated
myocardial infarction (STEMI), non-ST elevated myocardial infarc-
tion (NSTEMI) and unstable angina (UA). There are differences in
the composition of the coronary artery thrombi on each condition.
NSTEMI initiates with severe coronary artery narrowing, due to
development of platelet-rich white thrombi which is normally not
completely occlusive [28]; it is deﬁned by absence of ST-segment
elevation in the electrocardiogram and elevation of cardiac
biomarkers. STEMI starts with complete and prolonged coronary
artery narrowing involving formation of a ﬁbrin rich red clot
superimposed to the subjacent white thrombi [28]. It is probably
due to a higher plaque rupture [29] and characterized by ST-
segment elevation in the electrocardiogram and elevation of
myocardial necrosis biomarkers. UA characterizes by non-occlu-
sive thrombi [30] and absence of detectable release of the enzymes
and biomarkers of myocardial necrosis. A good diagnosis and
stratiﬁcation of patients is crucial for the management of patients
with ACS. In each case, the clinician is challenged to identify the
most effective and safest option of therapeutic treatments
available.
There are many risk factors associated with CVDs such as family
history, ethnicity and age, which cannot be changed. Other riskfactors that can be modiﬁed include smoke, hypertension, high
cholesterol, obesity, physical inactivity, diabetes, unhealthy diets,
and harmful use of alcohol.
As mentioned above, platelets play a pivotal role in the
pathophysiological mechanisms underlying many cardiovascular
diseases, especially ACSs, since they are implied in thrombus
formation after atheroma plaque rupture [31]. This is the reason
why molecules involved in platelet activation and aggregation are
the primary targets for treatment of ACSs [32]. Many efforts are
aimed at ﬁnding drugs that inhibit platelet activation; however
quite often it is difﬁcult to separate the therapeutic beneﬁts from
harmful effects because both pathological and physiological
functions of platelets are due to the same mechanisms. Here lies
the importance of investigation progress on antiplatelet drugs to
treat CVDs [33].
There exist some antiplatelet agents routinely used in the
treatment of ACSs. Cyclooxygenase-1 inhibitors (such as aspirin)
drastically reduce the mortality due to myocardial infarction, the
risk of subsequent cardiovascular events and ischemic complica-
tions due to percutaneous coronary interventions [34,35]. Other
drugs include thienopyridines (such as clopidogrel) which are
antagonists of ADP receptor P2Y12, and glycoprotein IIb/IIIa
inhibitors (such as abciximab or epiﬁbatide). Combination of dual
antiplatelet drugs (Cyclooxygenase-1 inhibitors and thienopyr-
idines) is routinely used in the prevention and treatment of ACSs
[36]. Current guidelines on percutaneous coronary intervention
recommend the administration of dual antiplatelet therapy [37].
However, prolonged treatment with dual or triple antiplatelet
drugs can develop either poor platelet responses, which lead to
antiplatelet resistance [38,39], or hyper platelet responses result-
ing in an increasing risk of bleeding [40]. For evident reasons the
study and development of novel antiplatelet agents, such as more
potent P2Y12, GPVI, and glycoprotein IIb/IIIa antagonists, are now
booming in order to reduce recurrent atherothrombotic events
without increasing bleeding risk.
1.2.2. Role of platelets in immunity
In the same way that platelets sense danger by recognizing
exposed subendothelial molecules after endothelial damage, they
can also sense danger by noticing the presence of pathogens or
pathogens-derived structures during infection and inﬂammatory
situations. It is known that there is a close relationship between
platelets and immunity, due to the sophisticated interplay of
platelets and bacteria. Thrombocytopenia (relative decrease of
platelets in blood) is a frequent occurrence in sepsis [41] and sepsis
is a signiﬁcant risk factor for thrombocytopenia in critically ill
patients [42]. During bacterial infection, direct interactions
between platelets and bacteria, leading to enhanced macrophagy,
may contribute to thrombocytopenia.
In this sense, platelets can be categorized as innate immune
cells specialized in pro-inﬂammatory activities. Platelets, by
inheritance from its predecessors (MKs), express ligands that bind
foreign structures, express receptors that ease the ingestion of
pathogens to destroy or inhibit them, secrete a large range of
factors involved in inter-cellular communication to mediate local
actions such as inﬂammation, and also are able to detect and
respond to different signaling molecules adapting their response
depending on the danger they face [18]. The ability of distinguish-
ing between different pathogens is due to the presence of pathogen
sensors and ligands on and in platelets. Functional pathogen
recognition receptors allow platelets to bind foreign microbial
invaders and combat them speciﬁcally. It has been recently
demonstrated that human platelets can discriminate between
various bacterial lipopolysaccharides isoforms, leading to the
differential secretion of soluble signaling/effective molecules from
platelets [43].
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In addition to their main role in hemostasis and thrombosis,
there are increasing evidences that platelets actively promote the
inﬂammatory process. Inﬂammation causes endothelial activation
which triggers leukocyte extravasation and adhesion to endothe-
lial cells, in a receptor-dependent process. After this, platelets are
rapidly recruited to sites of injury and infection. Inﬂammation
leads to an imbalance between procoagulant and anticoagulant
properties of the endothelium. The procoagulant effect is mediated
by TFN-a, the ﬁrst pro-inﬂammatory cytokine released at the site
of infection, while the anticoagulant effect is mediated by NO a
strong inhibitor of platelet activation.
The ﬁrst suggestion that platelets have a role in inﬂammation
camefromobservationsrelatedtoatherosclerosis. Theaccumulation
of subendothelial LDL, initiates the activation of endothelial cells,
characterized by loss of vascular integrity, cytokine production, and
the expression and shedding of leukocyte adhesive molecules [44],
thus triggering the subsequent process of inﬂammation. The role of
platelets in the early stages of atherosclerosis was ﬁrst recognized by
Steinhubl and Moliterno [45] and reinforced by the characterization
of the platelet releasate comprising many proteins with signiﬁcant
pro-inﬂammatory properties [46]. Moreover, several studies have
been focused on the adhesion of quiescent platelets to activated
endothelial cells endorsing the role of platelets in atherosclerosis
[47–49].
The contribution of platelets to inﬂammation associated with
other disorders has been less studied. However, platelets have been
related to many other inﬂammatory conditions such as rheumatoid
arthritis, inﬂammatory bowel disease, systemic lupus erythema-
tosus, migraine, inﬂammatory pulmonary disease and psoriasis.
This topic was extensively reviewed a few years ago by McNicol
and Israels [50].
1.2.4. Role of platelets in malignancy
The association between malignancy and platelets was ﬁrst
described in 1865 when Armand Trousseau observed that
migratory thrombophlebitis could be an indicator of malignancy
[51]. Since then, enumerable work has focused on the study of the
role of platelets in malignancy. Nowadays, there is a wide
knowledge of the bidirectional interaction of platelets and tumor
cells. Platelets promote tumor survival and progression, by forming
platelet–tumor aggregates which confers a survival advantage to
malignant cells [52,53], protecting them from immune system
surveillance [54,55] and enhancing metastatic potential [56].
Moreover platelets facilitate vessel wall adhesion [57] and tumor
cell invasion by penetration of the vessel wall [58]. Further than
this, platelets release growth factors that may enhance tumor cell
growth [59–61] and angiogenesis growth factors, which are
required for tumor angiogenesis, growth and metastasis
[57,62,63]. On the other hand, tumor cell-expressed proteins are
able to activate platelets, and the potential to activate them varies
among tumor cell lines [50].
1.2.5. Role of platelets in maintenance of vascular integrity
Platelets are known to support the semi-permeable function of
the endothelium being considered as critical guardians of vascular
integrity. First evidence of this platelet function was described by
Danielli in 1940 when he noted that platelets help to preserve the
barrier function of endothelium during organ perfusion [64]. Many
subsequent studies demonstrated that platelets continuously
support the barrier function of the resting endothelium [65,66]
and, in inﬂammation, they prevent or heal vascular injuries caused
by the inﬁltrating leukocytes. The platelet mechanisms of
maintaining vascular integrity not only involve the process of
platelet plug formation, but also the secretion of the various
platelet granules. Further information on this and other aspects ofthe role of platelets in vascular integrity can be found in a recent
review by Ho-Tin-Noé [67].
1.3. Platelet proteomics
Since platelets do not have nucleus, proteomics is an ideal tool
to approach their biochemistry. During the last decade proteomics
allowed the discovery of many platelet receptors and signaling
proteins, some of which are being studied as antithrombotic drug
targets. Initial studies were with platelets from healthy individuals
but in the last few years studies started focusing on the
identiﬁcation of platelet functional changes in normal and
pathological states, enriching the comprehension of platelet
biological function, searching for platelet biomarkers and new
antiplatelet agents [68]. Platelet proteomics has been recently
applied to understand the development of serious diseases, such as
hematological diseases and coronary heart disease. Fractionation
of samples in subproteomes (i.e. secretomes, exosomes and
microvesicles) is a good strategy to simplify the complexity of
the samples and to increase the success when searching for new
biomarkers [68]. Moreover, new technologies and strategies of
analysis (i.e. high sensitivity quantitative proteomics or depletion
of high abundant proteins) are being developed to access the low
abundance proteins. All this together encourages us to think that a
new era of biomarker and drug target discovery is starting to take
off, and it moves us one step closer to the practical application of
proteomics to the diagnosis and prognosis of CVDs as well as its
medical treatment [69]. Indeed, Burkhart et al. performed a recent
study revealing that >85% of the platelet proteome shows no
variation between healthy donors using an elaborate quantitative
analytical strategy [68], which is of great importance. This strategy
may be useful in the search for novel biomarkers, drug targets or
key mediators of platelet function. This reinforces the idea that
platelet proteomic studies can address issues of higher clinical
relevance such as differences in the response to antiplatelet
treatments or in the pathological potential of platelets in the
genesis of CVDs [70]. The following section will provide a guide for
sample preparation in platelet clinical proteomic studies.
2. Sample preparation for platelet clinical proteomic studies
2.1. Pre-analytical step
In platelet clinical proteomic studies it is essential to have a very
well established method to prepare samples. There are many
preparative steps from patient selection and blood collection to
platelet isolation and protein extraction, separation and analysis
(Fig. 1). All preparative steps have to be well deﬁned and comply
with strict quality control standards, in order to minimize the
technical variation among the specimens included in a study.
In patients or donors selection, it is important to establish very
well deﬁned and stratiﬁed groups with the least variability.
Attention should be paid to the drugs taken by the patients/donors
because they may have important effects in platelet function [71],
particularly antiplatelet drugs, and others such as anti-inﬂamma-
tory and antidepressive drugs, which may alter platelet activation
and aggregation [72]. Physical state and stress may also inﬂuence
platelet reactivity so – if possible – it is advisable to take blood at
the same time each day because circadian rhythms alter the
agreggability and adhesiveness of platelets [73]. Patients included
in a study must be deﬁned according to strict clinical or laboratory
criteria to avoid mixed populations which may cause confusing or
misinterpreted results. It is also important to consider the limited
amount of blood normally available from patients. Moreover, all
the necessary approvals by clinical ethics committees must be in
place before starting the study.
Fig. 1. Schematic workﬂow of platelet clinical proteomics research.
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have a highly sensitive nature and that minimal changes in the
moment of blood collection and preparation can activate ordeteriorate them. It is therefore of high importance to take all
necessary precautions during sample collection for platelet
proteomic studies, especially in the case of clinical biomarkers
20 P. Vélez, A. García / Translational Proteomics 7 (2015) 15–29research. There are several studies focusing on the step of platelet
isolation avoiding any platelet preactivation; some of them
reviewed by Everts et al. [74]. Blood should be taken from the
same source each time (i.e arterial or venous blood) and when the
individual is at rest. Zellner and Oehler [75] recently reported the
recommended parameters for blood extraction prior to a platelet
proteomics study. They advise to withdraw blood from the median
cubital vein, discarding the ﬁrst 2 mL, using a 21-gauge needle and
a light tourniquet. Collection tubes must not only prevent
coagulation but also preserve from spontaneous platelet activa-
tion. Tubes may inﬂuence platelet functions and proteomic studies
subsequently, so they must comply with several criteria. They
should be plastic-made and ideally contain sodium citrate (3.8%) as
anticoagulant. Tubes should be gently but slowly mixed immedi-
ately after blood extraction. Sample processing should be done as
soon as possible, ideally within the ﬁrst 1–2 h after blood
collection. Also environmental conditions must be adequate
because platelets are very sensitive to temperature and pH
changes, so we must be careful with these parameters during
transport and manipulation. Temperature must be between
20–25 C and pH must be controlled around 6.6 with acid-citrate
dextrose (ACD) in order to avoid aggregation. Another parameter to
consider is platelet concentration after isolation; it should never
exceed 109 platelets/mL, otherwise spontaneous activation may
occur.
All measures must be taken to minimize contamination with
proteins from other sources, since cellular contamination can
introduce artifacts on the proteome analysis. For this reason,
platelet isolation avoiding contamination with other cells or
plasma proteins is crucial for a successful proteome analysis. A key
point in platelet puriﬁcation is the separation of the platelet-rich
plasma (PRP) from white and red blood cells. This step can be
performed by blood centrifugation and careful separation of the
superior phase of PRP, or using leukocyte removal ﬁlters [76–78].
There is no standardized method for this, and one must be aware of
the drawbacks of both techniques. In the former case mentioned,
there is a risk of leukocyte contamination, while in the later a loss
of up to 25% of platelets is non-acceptable when it comes to clinical
samples. In our hands, mild centrifugation at 200  g during 20 min
results in a clear layer of leukocytes easily avoided, just pipetting
the upper third of the PRP [79]. A new development in platelet
isolation recently reported is cell sorting using magnetic microbe-
ads against the integrin b3 subunit [80].
The following step consists in platelet separation from plasma
and two strategies can be followed, one based on gel-ﬁltration and
other based on successive centrifugations. The ﬁrst method is
softer but it has other disadvantages as it does not allow
concentration of platelets. The second method is based on platelet
pelleting by centrifugation and resuspension in a suitable buffer. In
this method any centrifugation must be made in presence of
inhibitors such as prostacyclin (ﬁnal concentration 1 mM) to avoid
platelet activation. Different times and centrifugal forces are used,
but our and other groups have a great experience applying 1000  g
for 10 min [79]. Finally, it is advisable to resuspend platelet pellets
in a physiological buffer; we use modiﬁed Tyrode’s buffer (134 mM
NaCl, 0.34 mM Na2PO4, 2.9 mM KCl, 12 mM NaHCO3, 20 mM HEPES,
5 mM glucose, 1 mM MgCl2, pH 7.3). A ﬁnal centrifugation step at
the same speed is advisable to reduce plasma proteins to a
minimum level and obtain washed platelets. All centrifugation
steps must be performed at room temperature because cooling
may result in platelet activation [81].
Platelet counting can be done ideally using an electronic
particle analyzer such as a Coulter particle counter. Once
quantiﬁed, platelets are resuspended in an appropriate volume
of an adequate buffer (suitably modiﬁed Tyrode’s buffer) to leave
them at the desired concentration.2.2. Whole proteome and subproteome analysis
2.2.1. Whole proteome
Once platelets are isolated, the next step is to snap them in
order to prepare protein samples. The method selected determines
the results of proteomic analysis and depends on the downstream
process of the assay.
When it comes to whole platelet-proteome studies, disruption of
the platelet membranes is a mandatorystep. For this, two options are
available, using hypotonic buffers containing Nodinet P-40 (NP-40)
[78], Triton X-100 [82] or SDS [83] that cause cells swell and burst; or
lysing cells in liquid nitrogen. In each case it is necessary the
utilization of protease and phosphatase inhibitors in order to avoid
protein degradation by intracellular proteases and phosphatases
which remain active [84]. Platelet-membrane residues are removed
at high speed centrifugal forces (>10,000  g, 5 min) and the
supernatant is used for proteome analysis. Following lysis, platelet
proteins can be precipitated to purify and concentrate them. In our
hands, protein precipitation with 20% trichloroacetic acid (TCA) in
acetone (ﬁnal concentration) is a good option [79], but it can be also
made with an ethanol/dialysis method or commercial precipitation
kits. Zellner et al. reported that proteomic ﬁndings vary depending
on the precipitation method used [85], showing that the proper
choice of the method is of great importance. Beyond precipitation,
proteins may be solubilized in the appropriate buffer for further
studies. A representative 2D-map of the total platelet proteome is
shown in Fig. 2A.
2.2.2. Subproteome analysis
In some cases, and in order to increase the coverage of the
proteome analysis and the reduction of sample complexity, pre-
fractionation of the samples prior to electrophoresis must be done.
The study of subproteomes (i.e. exosomes, microvesicles, releasate,
organelles and membrane proteome) is of high interest and may
provide novel information on low-abundant proteins masked in
the whole proteome, thereby increasing the number of proteins
identiﬁed [86]. Some recommendations for subproteome analysis
are indicated below.
In the ﬁrst platelet proteome studies, based on 2-DE, membrane
proteins were severally underrepresented due to their low
abundance and low solubility in the 2-DE sample buffers. The
platelet membrane proteome encompasses all proteins embedded
in or associated with the various platelet lipid bilayers. Its study is
of high interest, since it includes receptors (which mediate cellular
responses on binding of a ligand), transporters (which move
substances across the membranes) and enzymes [87]. Identifying
the complete repertoire of membrane-proteins on resting and
activated platelets has relevant implications for understanding the
physiological and pathophysiological role of platelets. Interesting-
ly, it is estimated that more than 70% of all drug targets are
localized in plasma membranes [88]. Several techniques are used
to enrich integral membrane proteins, including chemical precipi-
tation and/or density gradient centrifugation, afﬁnity chromatog-
raphy and membrane shaving. The utilization of those techniques
followed by 1D SDS–PAGE and LC–MS/MS, MudPIT or COFRADIC,
greatly increased the power of membrane proteins identiﬁcation. A
study by Senis et al. took advantage of three different membrane
enrichment techniques, in combination with LC–MS/MS analysis,
to identify 136 transmembrane proteins expressed in human
platelets [89]. A more recent study by Lewandrowski et al. [90]
reported the highest number of platelet membrane proteins never
found (626).
The total platelet releasate consists of all the proteins and
other biomolecules released by activated platelets, including
microvesicles and exosomes contents. Platelet–granules contents
contribute to thrombosis, coagulation, atherosclerosis and
Fig. 2. 2-DE proteome proﬁle of the whole platelet proteome (A), platelet releasate (including microvesicles) (B), and plasma-derived microvesicles (C). Fifty micrograms of
protein were labeled with 400 pmol Cy2 DIGE ﬂuor. Proteins were separated by 2-DE. First dimension was on immobilized pH gradient (IPG) strips 4–7, 24 cm (GE Healthcare);
second dimension was by SDS–polyacrylamide gel electrophoresis (PAGE) on 11% gels. Following electrophoresis gels were scanned directly in a typhoon 9410 (GE
Healthcare). Representative images obtained in our lab are shown.
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explained by the evidence that proteins released by platelets were
found in human atherosclerotic plaques, which indicates that they
could be contributing to the pathogenesis of atherosclerosis [46,91].
Moreover, a recent report has revealed that platelet secretion is
kinetically heterogeneous in an agonist-responsive manner [92],
which is in line with our own data when comparing the releasate
from collagen – vs thrombin – stimulated platelets [106].
Some studies address the investigation of the whole platelet
releasate, while others focus on a speciﬁc part. In the case of whole
releasate studies (including MVs, and exosomes), ﬁrstly, platelets
are stimulated with agonists to induce protein secretion, avoiding
lysis. The releasate is then obtained by centrifuging platelet
samples after stimulation, in order to pellet and fully eliminate
them. Before centrifugation it is important to add prostacyclin to
prevent spontaneous aggregation during centrifugation (we
recommend 1 mM), and also protease and phosphatase inhibitor
cocktails to avoid sample degradation. We recommend performing
two centrifugation steps, the ﬁrst one at 1000  g for 10 min,
followed by a second centrifugation at 10,000  g for 2 min, both at
4 C. Supernatants containing the releasate can be concentrated in
Amicons to reduce sample volume (we use a 3 kDa Amicon,
centrifuging at 4000  g for 1 h and 15 min at 4 C, and
concentrating the sample to a ﬁnal volume of about 100 mL).
Samples should be ﬁnally precipitated to purify and concentrate
proteins and solubilize them in the desired buffer. In our hands,
precipitation with 20% TCA in acetone (ﬁnal concentration) is a
good option, but other precipitation methods can also be used.
Depending on the interest of the study, MVs can be removed prior
to analysis. To remove MVs, an extra ultracentrifuge step must be
done before protein precipitation; 1 h at 4 C and 50,000  g is a
good option [46].Proteome analysis of the platelet releasate can be carried out by
different strategies. Coppinger et al. in 2004 [46] published a
MudPIT-based study of the platelet releasate in response to
thrombin. The same group published another study using a
standard GeLC approach followed by MS/MS leading to the
conclusion that aspirin has a general moderating effect on the
amount of protein released regardless of the agonist [72]. Della
Corte et al. in 2008 published a quantitative analysis of platelet
releasate using 2D-DIGE [93]. A more recent study of the TRAP-
induced platelet releasate employed GeLC followed by LTQ-FT
resulting in a measurement of peptide fragments at a higher mass
accuracy than in any previous comparable study [94]. A
representative 2D-map of the platelet releasate, including micro-
vesicles, is shown in Fig. 2B.
As it was mentioned above, platelet-derived microvesicles are
part of the platelet releasate, but they can also be studied
independently by proteomics. Among 90% of the plasma micro-
vesicles are platelet-derived [95] and released into the circulation,
along with smaller vesicles of endosomal origin called exosomes.
MVs represent an important mode of intercellular communication
by serving as vehicles for transfer between cells of membrane and
cytosolic proteins [96], but are also involved in many other
functions such as coagulation, inﬂammation, intercellular com-
munication and tumor progression. MVs are known to have
important roles in the pathogenesis of various inﬂammatory
diseases such as atherosclerosis [97], and their number is
increased in the blood of patients with acute coronary syndromes
[98,99]. Since microvesicles are released into plasma, they are
typically prepared from it before or after platelet stimulation.
Plasma MVs are normally isolated for proteomic studies from
platelet-poor plasma (PPP), whereas platelet MVs are isolated after
activation of puriﬁed platelets. In any case, elimination of residual
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perform two consecutive centrifugations, the ﬁrst one for 10 min at
1500  g and the second one for 2 min at 15,000  g, both at 4 C.
Finally, the cell-free sample is subjected to ultracentrifugations to
pellet microvesicles. Ultracentrifugation forces and times vary
widely among groups, because there is no consensus protocol;
some groups apply 150,000  g for 90 min at 4 C [100,101],
100,000  g for 1 h at 4 C [102], 250,000  g for 1 h and 4 C [103],
for 200,000  g 2 h at 4 C twice [104]. We made a comparative
study to isolate plasma MVs including several of those protocols
and obtained the best result making centrifugations as follows:
PPP has to be processed until obtain platelet-free plasma (PFP), we
recommend two centrifuge steps for that as indicated above
(10 min at 1500  g and 2 min at 15,000  g at 4 C). PFP is then
diluted in HEPES buffer (10 mM HEPES/ 5 mM KCl/ 1 mM MgCl2/
136 mM NaCl2 (pH 7.4)) in a ratio of 1/2.5 and centrifuged for
90 min at 200,000  g and 4 C. After supernatant removal, the MVs
pellet is resuspended in 0.25 M KBr in order to eliminate soluble
serum proteins, and incubated on ice for 20 min. Samples are then
spun down for 90 min at 200,000  g and 4 C. Supernatant is
removed again and MVs pellet resuspended in PBS 1X and spun
down at the same conditions. The supernatant is ﬁnally removed
and the MVs pellet air dried before resuspension in the desired
buffer. It is important to notice that all the ultracentrifugation
protocols mentioned in this section not only sediment MVs, but
also exosomes. A representative 2D-map of the plasma MVs
proteome is shown in Fig. 2C .
The ﬁrst study of platelet-derived microvesicle proteome was
carried out by García et al., after platelet activation with ADP. They
performed a conventional 1-D SDS–PAGE followed by nano-
LC–MS/MS, identifying a total of 578 distinct proteins in these
MVs [100]; the complete list is available from the American
Chemical Society (http://pubs.acs.org). Two years later, Smalley
et al. published a proteomic comparative study of platelet-
derived and plasma-derived MVs using spectral count analysis
and isotope-coded afﬁnity tag (ICAT) labeling of proteins. This
analysis revealed 21 proteins expressed in human plasma-derived
but not platelet-derived MVs [101]. In a very recent study by
Capriotti et al., the platelet-derived microvesicle proteome was
analyzed again after platelet activation with ADP. This study,
based in a shotgun proteomics approach, led to the identiﬁcation
of 603 proteins, 243 of which were not previously identiﬁed
[105]. Besides this basic proteomic works, some clinical proteo-
mic studies related to platelet-derived or plasma-derived MVs
have been done in the last few years [104,106] because of the
relevance of MVs in the pathogenesis of several diseases.
As it happens with in the case of microvesicles, platelet-
released granules can be isolated and studied independently. The
release of platelet granules into blood has large consequences for
thrombosis, atherosclerosis and other pathological processes. Both
types of granules, a- and dense granules, are derived from MK-
multivesicular bodies [107]. When platelets are stimulated with
strong agonists, both types of granules are secreted following
calcium mobilization from intracellular stores, releasing their
contents into the plasma and contributing to the increase in
platelet membrane surface due to granule membrane fusion.
Regarding their function, platelet granules contribute to propaga-
tion of platelet activation, and moreover, to processes such as
coagulation, host defense, angiogenesis, wound healing, and
inﬂammation [108]. Storage pool deﬁciencies are rare genetic
disorders which may affect predominantly a-granules, dense
granules or both, and their symptoms illustrate perfectly the
importance of platelet secretory granules in hemostasis.
In a very recent study by Zufferey et al., platelets underwent
subcellular fractionation for granule enrichment, using sucrose
gradients, and centrifugal forces of 96,800  g for 135 min. Theyidentiﬁed 827 proteins, constituting the largest platelet granule
proteome qualitative dataset to date [109].
Alpha-granules contain a wide range of proteins and some
studies reported that there are distinct subsets of a-granules with
differential sorting of selected proteins into each [110]. Despite
being aware of the importance of a-granules, only one group has
speciﬁcally studied their proteome in detail. It was Maynard’s
group, in 2007, who addressed this challenge. They isolated
a-granules using a linear sucrose gradient method that allowed
them to identify 284 proteins [111]. Three years later the same
authors applied the same method to analyze the platelet proteome
of one patient suffering from gray platelet syndrome (GPS), a rare
inherited disorder characterized by mild to moderate thrombocy-
topenia with bleeding tendency and a marked decrease or absence
of platelet a-granules, and compared this patient to healthy
a-granules [112]. They found that soluble, biosynthetic cargo
proteins were severely reduced or undetected in GPS platelets,
whereas the packaging of soluble, endocytic cargo proteins was
only moderately affected.
Dense granules contain predominantly small molecules, such as
ADP, ATP, serotonin, calcium and polyphosphate [113]. A speciﬁc
study of the platelet dense granule content was done by
Hernández-Ruiz et al. [91]. Dense granules were isolated by
centrifugation using density columns. The low number of proteins
identiﬁed (40) is not surprising since dense-granules cargo are
mostly composed by small molecules.
Regarding quality controls, contamination with other blood cells
must be analyzed in the case of whole platelet proteome studies. This
can be done by immunoblotting using antibodies against speciﬁc red
or white cell proteins. The electronic particle analyzer mentioned
above can also give an indication of the presence of other blood cells,
based on counting cells above platelet size. In the studies of
subproteomes, quality controls must be made in order to ensure that
there are no proteins from other subproteomes in the isolated
subproteome. Moreover, in order to characterize speciﬁc subpopu-
lations such as exosomes or MVs, there are several useful tools to
check their purity, such as immunoblotting, FACS, immunogold
labeling or electron microscopy.
3. Platelet proteomics in cardiovascular disease-related studies
Over the last decade, the potential of proteomics has become
extensively recognized and its use for the study of complex
diseases has increased exponentially. There are hundreds of
platelet-proteomic studies, but it was only in the last few years
when several groups focused on platelet proteomics applied to
cardiovascular and arterial thrombosis diseases. In this section we
revise the most relevant proteomic studies on platelet-related
cardiovascular diseases and some other related conditions (Table 1
and Fig. 3).
3.1. CAD platelet proteome: searching for biomarkers and drug targets
To the best of our knowledge, there are four proteomic studies
searching for platelet biomarkers in CAD, two of them from our
group.
In the last few years our group started to study the functional
change experienced by platelets in ACSs applying 2-DE-based
proteomics combined with MS. Our aim was to expand the
knowledge about these functional changes and also search for
novel platelet biomarkers and potential drug targets for these
diseases. We performed two studies; the ﬁrst one focused on
NSTEMI patients [114] and the second on STEMI ones [115].
The ﬁrst study included 18 NSTEMI patients and 10 stable
coronary artery disease (SCAD) controls, matched by sex, age and
treatments. 2-DE analysis (24 cm, pH 4–7 and 10% SDS–PAGE)
Table 1
Platelet proteomic studies in CVD.
Authors Source sample Proteomic
approach
Main ﬁndings
Coronary artery disease
Parguiña et al. 2010
[114]
NSTEMI patients vs SCAD controls and healthy
donors.
2DE MALDI-TOF/
TOF
Variation in signaling, cytoskeletal and secreted proteins. Involvement of
signaling pathways (GPVI and aIIbb3). Sustain the idea of pre-activated
platelets in acute patients.
Parguiña et al. 2011
[115]
STEMI patients vs SCAD controls and healthy
donors.
2DE MALDI-TOF/
TOF
Variation in signaling, cytoskeletal and secreted proteins. Involvement of
signaling pathways (GPVI, aIIbb3 and aIIb1). Higher activation of GPVI in
STEMI patients. Uphold the idea of pre-activated platelets in acute patients.
Banﬁ et al. 2011
[116]
NSTEMI and SA patients vs SCAD controls and
healthy donors.
2DE LCQ-IT Changes in cytoskeleton, energy metabolism and protein degradation.
Alterations might be produced at MK level.
López-Farré et al.
2011 [117]
ACS patients vs CAD controls. 2DE MALDI-TOF
MALDI-TOF/TOF
Down-regulation of cytoskeleton, antioxidant system and energy metabolism.
Support the idea of decrease on platelet predisposition to activation and limited
platelet activity. Alterations might be produced at MK level.
Mateos-Cáceres
et al. 2010 [119]
SCAD ASA-resistant vs ASA-sensitive patients. 2DE MALDI-TOF/
TOF
Changes of proteins related to energetic metabolism, cytoskeleton, oxidative
stress and cell survival. Platelets from ASA-resistant patients may have a higher
apoptotic state.
Volpi et al. 2012
[121]
SCAD patients (SA) before coronary
intervention, after clopidogrel administration
and after PCI.
2DE MALDI-TOF/
TOF
Cytoskeletal, oxidative stress and energy metabolism changes. Clopidogrel
interrupt exocitosis and control enhanced platelet activation.
Azcona et al. 2012
[122]
SCAD patients suffering from type II diabetes
miellitus and treated with ASA or ASA +
clopidogrel.
2DE MALDI-TOF
MALDI-TOF/TOF
Dual antiplatelet therapy did not enhance the effect of aspirin. Patients have
lower platelet reactivity after dual antiplatelet therapy.
Hypertension
Sacristán et al. 2008
[71]
Hypertensive patients taking or not
Olmesartan medoxomil.
2DE MALDI-TOF
MALDI-TOF/TOF
Olmesartan medoxomil alters the expression of some platelet proteins. Up-
regulation of a gelsolin precursor suggests reduction in platelet activation.
Decrease of several other proteins suggests reduced antioxidative requirement
of platelets in treated patients. Alteration may be produced at MK level.
Gebhard et al. 2011
[125]
Rats induced angiotensin II- dependent
hypertension vs normotensive rats.
2D-DIGE MALDI-
TOF/TOF FT-ICR
Cytoskeletal changes and increased degradation. Suggest ongoing signaling in
platelets from hypertensive rats and acceleration in the aging of platelets.
Changes are consistent but reversible.
Diabetes
Randriamboavonjy
et al. 2012 [127]
Type 2 diabetic miellitus patients before and
after treatment with pioglitazone
2D-DIGE MALDI-
TOF/TOF
Changes in calpain substrates and several other proteins not previously related
to calpain. Conclude that calpain inhibition may be effective to decelerate
atherothrombosis development preserving platelet function.
Subproteomes
Hernández-Ruiz
et al. 2007 [91]
Platelet-derived dense granules from healthy
donors. Includes abdominal aortic aneurism
patients.
2DE MALDI-TOF/
TOF LC-MS/MS
Increasing of 14-3-3z forming patches in the luminal side of atherosclerotic
plaques in abdominal aortic aneurism patients. This protein plays a relevant
role in the progression of atherosclerosis.
Vélez et al. 2014
[106]
Plasma-derived MVs from STEMI patients vs
SCAD controls and healthy donors.
2D-DIGE MALDI-
TOF/TOF LC-MS/
MS
Changes in proteins related to inﬂammation, thrombosis and cardiovascular
disease.
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features were successfully identiﬁed by MS (MALDI-TOF/TOF), and
corresponded to 22 ORFs. A systems biology approach using
ingenuity pathway analysis (IPA) revealed that 16 of these proteins
are interconnected in a network related to cell assembly and
organization and cell morphology. Fourteen of those proteins are
either signaling or cytoskeletal and nine are known to play a major
role in platelet activation by aIIbb3 and/or GPVI receptors,
suggesting that these pathways may play a relevant role in
platelet activation associated with NSTEMI. We validated two
signaling proteins by 2-DE western blotting whose differences
were due to PTMs. We also validated the secreted protein SPARC
and found it down-regulated in NSTEMI patients; which is
consistent with platelet secretion associated to platelet activation
in NSTEMI patients. Moreover this study includes patient
monitoring during a 6-month follow-up revealing that those
proteins returned to normal levels after that time. Our data suggest
higher platelet activation in NSTEMI patients.
In the second study, the platelet proteome of STEMI patients
(N = 11) and SCAD controls (N = 15) was compared. The analytical
approach was the same than in the previous study: 2-DE (24 cm,
pH 4–7 and 10% SDS–PAGE) followed by MS (MALDI-TOF/TOF). In
this case, we found 56 differences between groups, corresponding
to 42 ORFs. IPA analysis revealed that 35 of the 42 differentiallyregulated proteins identiﬁed are interconnected in a network
related to tissue and cell morphology and the top molecular and
cellular functions are cell-to-cell signaling and interaction, cellular
assembly and organization and cell morphology (as in the NSTEMI
study). We validated p-Src and Crkl. The up-regulation of the
active form of Src (Src-PTyr418) in STEMI suggests a primary role
of pathways related to GPVI, aIIb1 and aIIbb3. Moreover, IPA
revealed 3 platelet signaling pathways related to platelet
activation in ACSs: acting cytoskeleton signaling, integrin-linked
kinase signaling, and GPVI signaling. Furthermore, this study
included an independent experiment of activation with the GPVI-
speciﬁc agonist collagen-related peptide (CRP) in healthy, SCAD
and STEMI groups (6 patients per group) revealing a higher
activation of GPVI signaling in platelets from STEMI patients.
Additionally we performed a 6-month follow-up analysis, as in the
NSTEMI study, which revealed a decrease in the number of
differences with time.
Besides the above studies, in 2011 Banﬁ et al. [116] published a
study comparing the platelet proteome of patients with NSTEMI
(N = 14) and SA (N = 12) with healthy donors (N = 10). The analysis
was based on 2-DE (17 cm, pH 3–10 and 7–17% SDS–PAGE)
followed by MS (LCQ-IT). They identiﬁed 6 differentially expressed
proteins: two involved in energy metabolism (OGDH and LDH),
three related to cytoskeleton-based processes (g-actin, coronin 1B
Fig. 3. Platelet proteomics in cardiovascular disease: main studies carried out to date. References are indicated; further information can be found in Table 1. WPP, whole
platelet proteome. *Plasma-derived MVs include a majority of MVs coming from platelets.
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OGDH and g-actin levels were signiﬁcantly increased in platelets
from both patient groups compared to the healthy control group,
whereas LDH was higher only in patients with NSTEMI. Coronin 1B
and PSB8 were less expressed in platelets from both patient
groups, and basic forms of pleckstrin exhibited the same behavior.
In agreement with our results [114], the differences they found
were related to cytoskeletal remodeling, platelet activation and
proteolytic activity. They propose that platelets from NSTEMI
patients suffer from an increase in the energy metabolism and
attribute the differences to the atherosclerotic process. Authors
suggest that alterations might be produced at MK level.
Finally, and also in 2011, López-Farré et al. [117] compared the
platelet proteome of a group of patients with ACS (N = 16) and CAD
controls (N = 26), combining 2-DE (18 cm, pH 3–10 and 10%
SDS–PAGE) with MS (MALDI-TOF or MALDI-TOF/TOF). They
focalized their study on proteins related to glycolysis, because
platelet energetic production is mainly dependent on glycolysis, on
proteins involved in cytoskeleton (that regulates most of platelet
activities), and on the platelet antioxidant system (protects
platelets from oxidant agents, which are important platelet
stimulators). 2-DE analysis revealed that proteins involved in
activities aforementioned were downregulated in platelets from
ACS patients compared to CAD platelets. From a biological point of
view, a decrease of the antioxidant system in ACS platelets might
predispose those patients to easier platelet activation by pro-
oxidant agents produced during acute coronary event, turning
platelets unable to prevent their activation by oxygen free radicals
[118]. Moreover, reduction on the expression of both cytoskeleton
and energetic-metabolism-related proteins, may suggest a de-
crease on platelets predisposition to be activated. Broadly, they
conclude that differentially expressed proteins on platelets from
ACS patients seem to reﬂect easier platelet activation (diminished
antioxidant system) and a limited platelet activity (reduction in the
expression of cytoskeleton and glycolytic-related proteins).
Therefore, the authors hypothesize that some of the inﬂammatory
compounds released from the inﬂamed plaque may play as signalsto produce these “bewildered” platelets from megakaryocytes,
days before the clinical onset of the acute event.
3.2. CAD platelet proteome: inﬂuence of treatment
Recent platelet proteomic studies in cardiovascular diseases
were also made to assess how the platelet proteome varies
depending on the treatment used. There are several evidences that
some ACS patients do not respond well to the treatment with
acetyl salicylic acid (ASA). The reason why these patients show
inadequate platelet inhibition by ASA is still unclear and this is why
Mateos-Cáceres et al. performed a platelet proteome analysis
including 51 stable coronary ischemic patients [119]. They
compared ASA-resistant (N = 25) and ASA-sensitive (N = 26)
patients by 2-DE (18 cm, pH 3–10 or pH 4–7 and 10% SDS–PAGE)
followed by MS (MALDI-TOF/TOF). They found that platelets from
those patients differ in terms of the expression of proteins related
to energetic metabolism, cytoskeleton, oxidative stress and cell
survival. ASA-resistant showed a downregulation on three proteins
related to cytoskeleton (gelsolin precursor types 2 and 3, F-actin
capping) which control the assembly and disassembly of actin
ﬁlaments essential in platelet shape change. In addition proteins
involved in energetic metabolism (disulphide isomerase isotype 1,
glutathione S-transferase, 1,6-bisphosphate aldolase) were down-
regulated in ASA-resistant patients, unless glyceraldehyde 3-
phosphate dehydrogenase, which suggests that platelets from
these patients have a reduced protection against oxygen free
radicals which makes them more prone to activation. Regarding
stress and cell survival, they found that disulphide isomerase
isotope 1 was increased in ASA-resistant patients whereas some
heat shock proteins were decreased. No changes were observed in
inﬂammatory proteins. Taken all these results together, authors
conclude that platelets from ASA-resistant patients may have a
higher apoptotic state than ASA-sensitive ones.
Clopidogrel, which is a thienopyridine-class antiplatelet agent
used to inhibit blood clots in CVDs, is widely used as platelet
inhibitor for coronary angioplasty procedures [120], such as
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their attention on the fact that ACS patients undergoing clopidogrel
treatment and elective PCI may have altered platelet reactivity, and
decided to study the platelet proteome in order to shed light over
the molecular mechanisms that regulate platelet reactivity in this
context. The proteome study was based on 2-DE (18 cm, pH 3–10
and 12.5% SDS–PAGE) followed by MS analysis (MALDI-TOF/TOF),
and included 20 SCAD patients suffering from stable angina. This
analysis was based on the comparison of platelets taken at three
time points: before coronary angiography (T0), 12 h after 600 mg of
clopidogrel administration (T1) and 24 h after PCI (T2). Moreover,
they included a study of clopidogrel response and platelet reactivity
(using ﬂow cytometry and aggregation tests) which showed that a
clopidogrel-loading dose produced a signiﬁcant inhibition in all
markers of platelet activation. Among the 24 proteins found
differentially expressed, 18 were identiﬁed by MS analysis. These
included oxidative stress-related proteins (heat shock 70 kDa
protein 5, snit-stress induced phosphoprotein 1), energetic
metabolism-related proteins (nucleoside diphosphate kinase B,
protein-L-isoaspartate(D-aspartate) O-methyltransferase, ubiquitin-
like modiﬁer-activating enzyme 1) and cytoskeleton rearrange-
ment proteins (proﬁlin-1, calapin, thrombospondin, a-soluble NSF
attachment protein). These proteins seem to be announcing
changes associated with platelet activation and clopidogrel
response, like controlling enhanced platelet activation in SCAD
patients or interrupting platelet exocitosis processes.
In the same year, Azcona et al. [122] compared the effect of dual
antiplatelet therapy (clopidogrel + aspirin) with respect to aspirin
treatment, on the platelet proteome of type-2 diabetic patients
with stable coronary artery disease. This study included 57 patients
randomized to receive dual (N = 29) or single (N = 28) antiplatelet
therapy. A 2-DE (18 cm, pH 3–10 and 10% SDS–PAGE) was
performed for each patient. Identiﬁcations were by MS (MALDI-
TOF or MALDI-TOF/TOF) focusing on the study of platelet proteins
associated with cytoskeleton, energetic metabolism, oxidative
stress and inﬂammation. Between the two different antiplatelet
strategies, differences were found in actin-binding protein
isotypes 2 and 5 (cytoskeleton and contractile system-related
proteins) which were found upregulated in single antiplatelet
therapy. Also lactate dehydrogenase (protein associated with
energetic metabolism and oxidative stress) was found upregulated
in platelets from patients with single antiplatelet therapy.
Similarly, FBC isotope 5, immunoglobulin heavy chain and RAB7B
isotypes 1 and 6 (all of them related to inﬂammation) were found
upregulated in platelets from patients treated with aspirin. They
also tested plasma levels of platelet factor 4 (PF4), a marker of
platelet activity, without ﬁnding any differences between both
groups. On the basis of PF4 circulating levels, it seems that dual
antiplatelet therapy did not enhance the effect of aspirin. Taken in
mind all before mentioned, authors suggest that there exist lower
platelet reactivity after dual antiplatelet therapy but further
studies are needed to assess the implications of these changes in
platelet functionality.
3.3. Hypertension: variations in the platelet proteome and inﬂuence of
treatment
Hypertension is the major risk factor of cardiovascular
problems. Platelets from patients suffering from hypertension
show a basal state of pre-activation and a tendency to aggregate
[123], and it is known that some angiotensin II receptor blockers
(ARBs) inhibit human platelet activation in vitro [124]. This is the
reason why several researchers conducted their efforts to the study
of platelet-proteomics in hypertension.
Sacristán et al. [71] focused on the study of the platelet
proteome of moderate hypertensive patients before and aftertreatment with Olmesartan medoxomil, which is a new highly
potent and selective ARB, which exhibits pleiotropic effects that
are not fully understood. This study included 13 patients with
moderate hypertension who were randomized to have or not a
6 month treatment with Olmesartan medoxomil. They found that
patients treated with this drug showed signiﬁcantly reduced
systolic blood pressure, proteinuria, total cholesterol and LDL-
cholesterol in plasma. Moreover this treatment did not modify the
circulating plasma levels of different pro-inﬂammatory proteins,
but changed the expression of some platelet proteins. Using 2-DE
(pH 3–10 or pH 4–7 and 10% SDS–PAGE) combined with MS
(MALDI-TOF or MALDI-TOF/TOF) they demonstrated that the drug
altered the expression of some platelet proteins. They found an
increase in the expression of gelsolin precursor isotype 4,
suggesting a reduction in platelet activation. Also it was found a
decrease of tropomyosin-b chain isotypes 1–5, leukocyte elastase
inhibitor and chloride intracellular channel-protein isotype 1,
which suggests a reduced antioxidative requirement of platelets in
treated patients. They conclude that this differential expression
may be related to some action of the drug predictably at
megakaryocyte level.
Another platelet-proteome study related to hypertension, but
in rats, was done by Gebhard et al. [125]. They induced angiotensin
II-depended hypertension in rats following two strategies: feeding
rats with indole-3 carbinol (IC3, N = 10) or subcutaneously infusing
angiotensin II (ANG II, N = 7). Fourteen days later, authors
compared the platelet proteome of these rats with a control
group of normotensive rats after placebo treatment (N = 7 and
N = 10, respectively). Proteomic analysis was based on 2D-DIGE (pH
4–7 and 12.5% SDS–PAGE) and MS (MALDI-TOF/TOF or FT-ICR).
Sixty-six altered proteins were found in feeding IC3 rats and 157 in
ANG II infused rats, 45 of which were common to both groups.
Proteins differentially regulated were mostly cytoskeletal protein
fragments, which might result from ongoing signaling in the
platelet. This is in agreement with the observation that platelet
function is increased in hypertensive patients [126]. This protein
degradation could also produce acceleration in the aging of
platelets. These changes on the platelet-proteome of rats were
consistent and reversible.
3.4. Diabetes: variations in the platelet proteome and inﬂuence of
treatment
Although diabetes is not a CVD itself, their relationship is very
well known, since platelets from diabetic patients are hyper
reactive and have increased adhesiveness, aggregation, degranu-
lation and thrombus formation. All of these characteristics make
diabetics vulnerable to vascular disease development. In this
context Randriamboavonjy et al. [127] developed a platelet
proteome study of type 2 diabetic miellitus patients. Among other
experiments they performed a 2D-DIGE analysis (18 cm, pH 3–10
and 12% SDS–PAGE) of platelet proteins from the same diabetic
patient before and after treatment with Pioglitazone, which
increases insulin sensitivity and has deep effects on platelet
proteome. Protein identiﬁcation was by MALDI-TOF/TOF. Among
the proteins identiﬁed in the analysis, there were calpain
substrates (i.e. talin-1 and ﬁlamin A) and some other proteins
not previously linked with calpain (i.e. septin-5, ILK and glycerol-3-
phosphate dehydrogenase 2). With these results, those obtained in
mice, and the studies that show a beneﬁcial effect of calpain
inhibition in vascular disease, the authors conclude that since
diabetes-induced platelet dysfunction is mediated largely by
calpain activation, calpain inhibition may be an effective way to
decelerate atherothrombosis development and to preserve platelet
function.
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As it was mentioned earlier in the sample preparation section,
the study of subproteomes is of great interest in order to obtain
novel information masked in whole proteome analyses by high
abundant proteins. In this regard, some proteomic studies are
targeting platelet subproteomes. This is the case of the study
published in 2007 by Hernández-Ruiz et al. [91] who performed a
proteomic study of platelet-derived dense granules. This study was
made in healthy donors by 2-DE (11 cm, pH 3–10 or 5–8) followed
by MS (MALDI-TOF or LC-ESI MS/MS). They excised 20 protein
spots from the gel which correspond to 40 proteins, most of them
previously described as platelet proteins, but without knowledge
of their place of origin. Among those proteins they focused their
attention on the study of 14-3-3z which is a protein released by
activated platelets [46]. This protein is also associated with
intercellular signaling and regulation in platelets in conjunction
with vWF receptor, GPIb-V-IX [128]. Moreover a recent study has
identiﬁed 14-3-3z as a platelet signaling protein that is tyrosine
phosphorylated following GPVI activation [129]. Hernández-Ruiz
et al. conﬁrmed the presence of high levels of this protein in
platelet dense granules by western blot, immunoﬂuorescence and
functional analysis of platelet secretion. In addition, as it had been
shown that some proteins secreted by platelets contribute to
atherosclerosis progression, they evaluated the localization of 14-
3-3z in sections of the aorta wall from 14 patients with abdominal
aortic aneurism, which present atherosclerotic plaques. Results
show that those patients have 14-3-3z forming patches on the
extreme luminal side of atherosclerotic plaques, which suggests
that this protein may come from activated platelets in the cavity of
the artery. Overall, authors suggest that 14-3-3z might play a
relevant role in the progression of atherosclerosis.
Microvesicles are known to be increased in the blood of patients
with acute coronary syndromes, and STEMI in particular [130],
among many other pathological conditions, moreover inﬂamma-
tory disease. Plasma microvesicles are constituted primarily by
platelet derived MVs. With that in mind, our group decided to
study the proteome of plasma-derived MVs from patients with
STEMI compared to stable coronary artery disease (SCAD) controls
[106]. Ten STEMI patients and 10 matched SCAD controls were
used for proteomic analysis, which was based on high-resolution
2D-DIGE (24 cm, pH 4–7 and 11% SDS–PAGE) and MS (LC–MS/MS).
We found 117 protein features differentially regulated, and from
those we successfully identiﬁed 102 corresponding to 25 ORFs.
Most proteins identiﬁed were related to inﬂammatory response,
thrombosis and cardiovascular disease. Indeed 11 proteins could be
located in a network related to infarction and 10 in a network
related to atherosclerosis, as it revealed the systems biology
approach (IPA). Among the proteins identiﬁed, we report that a2-
macroglobulin isoforms, ﬁbrinogen (both related to thrombo-
genesis), and viperin (related to atherosclerosis) are up-regulated
in plasma-derived MVs from STEMI patients; whereas ITIH4, an
anti-inﬂammatory protein, is down-regulated. Validations were by
1D- and 2D-western blotting using an independent cohort of
patients (15 STEMI, 13 SCAD and 10 healthy donors). The up-
regulation of a2-macroglobulin isoforms and ﬁbrinogen indicates
that MVs might be playing a relevant role at local level in the
atherothrombotic events that lead to a myocardial infarction.
Meanwhile, the detection of viperin in atherosclerotic lesion may
be linked to an active immune status in the lesion.
3.6. Key conclusions from platelet proteomic studies related to CVD
The studies mentioned above reﬂect the hyperactive state of
platelets in CVD, especially in CAD. The studies carried out on
platelets from ACS patients reﬂect an up-regulation of signalingand cytoskeletal proteins, as well as a down-regulation of
antioxidant proteins. These data are in agreement with increased
platelet activation levels in ACS, which might be responsible for the
atherothrombotic events related to the acute event. Regarding CAD
studies related to the effect of drug treatments, proteome studies
show that dual antiplatelet treatment seems to diminish platelet
reactivity, as expected. On the other hand, results indicate that
platelets from ASA-resistant patients may have a higher apoptotic
state than ASA-sensitive ones.
Regarding other CVD-related pathologies, such as hypertension
and diabetes, results are also in line with the hyper-reactive state of
platelets in those pathologies. In the case of diabetes, results seem
to indicate that platelet dysfunction is mediated by calpain
activation so calpain inhibition is proposed as a way to decelerate
atherothrombosis development and preserve platelet function.
Studies related to subproteomes, primarily focused on MVs, are
also in line with the platelet studies. Thus, the proteome analysis of
MVs from myocardial infarction patients shows the up-regulation
of proteins involved in atherothrombosis on those patients. This
suggests that activated platelets are releasing MVs at local level
that contribute to the atherothrombosis responsible for an ACS.
Overall, the studies carried out to date are pretty coherent and
give clues on novel potential platelet drug targets to prevent/treat
atherothrombosis-related CVD. Current data pave the way for
future studies that should focus on validating the results obtained
so far in larger cohorts of patients and pathological conditions.
4. Concluding remarks
With the beginning of the 21st century and the sequencing of
the human genome a new era began for biomedical research. Rapid
advances in – omics technologies and systems biology allowed a
thorough analysis of biological samples both from patients and
healthy individuals. The enormous expectations and optimism
present in the early days were followed by caution and skepticism
because a lot of money was invested in – omics research and yet
results were not being obtained so rapidly. Analytical problems
appeared that had, and still have, to be tackled; a good example of
this is the proteomic analysis of plasma and serum. As a
consequence, the initial expectations led to some sort of frustration
as the number of biomarkers and drug targets identiﬁed by these –
omic technologies, including of course proteomics, was not as high
as initially expected. Time is needed to address all the various
challenges that appeared on the way, and this is true especially for
proteomics where recent advances in mass spectrometry-based
technologies for protein analysis and quantitation are bringing
new prospects to the ﬁeld and allowing solving many of the
analytical problems mentioned above.
Platelet proteomics also faced the same challenges than
proteomics in general had to face. The fact platelets lack of a
nucleus makes them easier to prepare for proteome analysis. Besides
whole proteome analysis, subcellular fractionation and the analysis
of signaling pathways, microvesicles and the releasate have
provided additional relevant information so we can today say that
an important proportion of the platelet proteome has been
uncovered. This deﬁnitely paves the way for future quantitative
studies can be applied to biomarker discovery. Indeed, it has been
only in the last 7 years that platelet proteomics has been applied to
clinical studies, and more precisely to cardiovascular research. This
review tried to show not only recent advances present in the
literature but also some of the analytical challenges that the study of
the platelet proteome has to face when dealing with clinical
samples. The task is not easy but with appropriate methodological
standardization procedures for platelet preparation, subcellular
fractionation and releasate/microvesicles isolation, there is no doubt
it will be easier to deal with these delicate samples for downstream
P. Vélez, A. García / Translational Proteomics 7 (2015) 15–29 27proteomic analyses. This will also allow better inter-lab reproduc-
ibility for a given assay. Recent advances in quantitative proteomics
will also allow obtaining promising results for biomarker and drug
target discovery related to platelets, as already shown by our group
and by other recent studies mentioned in this review. Obviously,
inter-lab reproducibility regarding proteomic results is more
difﬁcult given the high variety of proteomic approaches that can
be used depending on the proteomic platform present in a particular
laboratory; nevertheless, the aim should be that laboratories with
the same platform yield similar results. We are still in the early days
of platelet proteomics applied to clinical studies, and more precisely
to the study of cardiovascular disease; however, recent advances in
the ﬁeld allow us to be moderately optimists in the hope that this
time expectations will not be frustrated.
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